According to the report, the penetration of advanced bio-technology is increasing and pharmaceutical companies are collaborating with fermentation services, creating the growth prospects.
Fact.MR study reveals that the drug commercialization with contract manufacturing organizations are creating bulk productions and the increasing R&D activities is driving the growth of contract pharmaceutical fermentation services
Furthermore, the growing prevalence of wide range of disease such as cancer, diabetes, cardiovascular diseases, rheumatoid arthritis, hemophilia, and others are prompting a high demand for the high production of time-efficient drug development, bolstering the growth of the market.
“Leading players are focusing in luring the pharmaceutical companies by integrating advanced biotechnology and investing in research and development activities in diverse applications,” says the Fact.MR analyst.
Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=1517?AS
Key Takeaways
- Contract pharmaceutical fermentation services to exceed US$ 4 Bn by 2026
- North America to dominate the market backed by high presence of pharmaceutical industries
- By products, biotherapeutics to lead the market, followed by vaccines
- Biotechnology companies expected to emerge as a potential end-user
- Peptides and plasmids to growth to be sluggish through 2021
Prominent Drivers
- Rising demand for biosimilar and biologic manufacturing to provide growth opportunities for manufacturers, bolstering the growth
- Diverse application of Contract Pharmaceutical Fermentation Services procedures in developing time-efficient drug development to create growth prospects
- Amid surging production, pharmaceutical companies collaborating with contract pharmaceutical fermentation services to foster the sales
Competitive Landscape
AbbVie, Inc., Aumgene Biosciences, EKF Diagnostics-Stanbio, Boehringer Ingelheim International GmbH, Biocon, AMRI, Pfizer, Lonza, CordenPharma International, and Fujifilm Holdings Corporation are some of the manufacturers profiled by Fact.MR. According to the study, the market is fragmented in nature and key players are focusing on strategies such as R&D and mergers and acquisition for future growth prospects.
In March 2021, AbbVie Inc., announced the extension of review of supplemental new drug application of Upadacitinib for the treatment of adults with active psoriatic arthritis. The research and development-based biopharmaceutical company announced that the FDA has extended the review period and are expected to initiate the research on other immune-meditated diseases.
Likewise, another leading player, Boehringer Ingelheim International GmbH and the Lieber Institute for Brain Development announced a collaboration and new research focused on development of novel centrally acting COMT (catechol-O-methyltransferase) inhibitors for the potential treatment of cognitive deficits in a spectrum of neuropsychiatric disorders, including schizophrenia, advancing the revenues.
Segmentation
The Fact.MR report on contract pharmaceutical fermentation services offers a comprehensive taxonomy of the contract pharmaceutical fermentation services market on the basis of contract pharmaceutical fermentation service type, platform, product type, and end user of contract pharmaceutical fermentation services.
On the basis of service type, the global contract pharmaceutical fermentation services market has been segmented into development services and commercial services. On the basis of platform, the global contract pharmaceutical fermentation services market has been segmented into bacterial and fungal/yeast.
Based on product type, the global contract pharmaceutical fermentation services market has been segmented into bio-therapeutics, enzymes, peptides, plasmids, cytokines & growth factors, vaccines, others (fusion proteins, etc.).
By end user, the global contract pharmaceutical fermentation services market has been segmented into pharmaceutical companies, biotechnology companies, animal health companies, and academic & research institutes. Based on region, the contract pharmaceutical fermentation services market has been bifurcated into North America, Latin America, Europe, and Asia Pacific excluding Japan (APEJ), Japan, and the Middle East & Africa (MEA).
More Insights on the Contract Pharmaceutical Fermentation Services Market
In its latest report, Fact.MR offers unbiased analysis of the global Contract Pharmaceutical Fermentation Services market. The report divulges essential insights on Contract Pharmaceutical Fermentation Services market on the basis of platform (bacterial and fungal/yeast), service type (development services and commercial services), product type (biotherapeutics, enzymes, peptides, plasmids, cytokines & growth factors, vaccines and others), end-user (pharmaceutical companies, biotechnology companies, animal health companies, and animal health companies institutes), and regions (North America, Latin America, Europe, Japan, APEJ, and Middle East and Africa)
Request more information about Report Methodology:
https://www.factmr.com/connectus/sample?flag=RM&rep_id=1517?AS
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Email : sales@factmr.com